首页> 外文期刊>International journal of infectious diseases : >The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: Use of colistin in a population of lower body weight
【24h】

The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: Use of colistin in a population of lower body weight

机译:在越南的重症监护病房使用粘菌素的功效和肾毒性:在体重较轻的人群中使用粘菌素的情况

获取原文
           

摘要

Background: There has been a growing need for colistin as a key drug for the treatment of MDR-GNB infection. Information on colistin use in Asian population is limited. Methods: A retrospective observational study was conducted to assess the efficacy and nephrotoxicity in critically ill adult patients who received intravenous colistin for MDR-GNB infection in the intensive care unit (ICU) at Bach Mai Hospital in Hanoi, Vietnam. Colistin was administered according to the dosing guideline that was based on pharmacokinetic, pharmacodynamic and toxicodynamic principles, adjusted by body weight and creatinine clearance. Results: Twenty-eight eligible patients were included. The mean patient age was 60+/-20.4 years. The mean body weight was 53+/-8.6kg. The mean daily dose of colistin was 4.1+/-1.6 MIU, and the mean cumulative dose of colistin was 48.2+/-22.8 MIU. Colistin therapies were classified as clinically effective in 19 (67.9%) cases. Six (21.4%) patients developed nephrotoxicity during the study period according to RIFLE criteria. Conclusion: A personalized dosing protocol of colistin was effective, with low nephrotoxicity, among critically ill Vietnamese patients with low body weight. Further studies are warranted for assessing the efficacy and toxicity in a larger cohort.
机译:背景:粘菌素作为治疗MDR-GNB感染的关键药物的需求不断增长。关于亚洲人中粘菌素使用的信息有限。方法:进行了一项回顾性观察研究,以评估在越南河内巴赫迈医院的重症监护病房(ICU)接受静脉内粘菌素治疗MDR-GNB感染的重症成年患者的疗效和肾毒性。根据基于药物代谢动力学,药效学和毒理学原理的剂量指导原则施用共利斯汀,并根据体重和肌酐清除率进行调整。结果:包括28名符合条件的患者。患者平均年龄为60 +/- 20.4岁。平均体重为53 +/- 8.6kg。大肠菌素的平均日剂量为4.1 +/- 1.6 MIU,大肠菌素的平均累积剂量为48.2 +/- 22.8 MIU。共利斯汀疗法被分类为19例(67.9%)临床有效。根据RIFLE标准,在研究期间有六名(21.4%)患者出现了肾毒性。结论:对于体重较轻的危重越南患者,大肠菌素的个性化给药方案是有效的,且肾毒性低。有必要进行进一步的研究以评估较大人群的疗效和毒性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号